Top Biotech Stocks To Watch Today – November 8th

Moderna, Natera, and AbbVie are the three Biotech stocks to watch today, according to MarketBeat’s stock screener tool. Biotech stocks are shares of companies that use biology and biotechnology to develop products such as medicines, vaccines, and diagnostic tests. For investors, they can offer significant growth potential, but their value may be especially volatile because it often depends on clinical-trial results, regulatory approvals, and access to funding. These companies had the highest dollar trading volume of any Biotech stocks within the last several days.

Moderna (MRNA)

Moderna, Inc., a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.

Shares of Moderna stock traded up $12.73 on Friday, hitting $254.19. 16,295,043 shares of the company’s stock traded hands, compared to its average volume of 17,257,506. Moderna has a 52-week low of $22.28 and a 52-week high of $267.50. The company has a quick ratio of 2.18, a current ratio of 2.29 and a debt-to-equity ratio of 0.09. The stock has a market cap of $101.48 billion, a P/E ratio of -35.80 and a beta of 1.16. The firm’s 50-day moving average is $191.85 and its 200 day moving average is $91.51.

Natera (NTRA)

Natera, Inc., a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.

NASDAQ:NTRA traded down $53.09 during trading hours on Friday, reaching $310.67. 5,775,619 shares of the stock were exchanged, compared to its average volume of 1,711,005. The stock has a market capitalization of $44.78 billion, a P/E ratio of -272.52 and a beta of 1.55. The firm has a 50 day simple moving average of $380.25 and a 200-day simple moving average of $269.68. Natera has a 52 week low of $181.00 and a 52 week high of $437.41.

AbbVie (ABBV)

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn's disease; Rinvoq to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, ulcerative colitis, and Crohn's disease; Imbruvica for the treatment of adult patients with blood cancers; Epkinly to treat lymphoma; Elahere to treat cancer; and Venclexta/Venclyxto to treat blood cancers.

ABBV stock traded up $3.27 during trading on Friday, hitting $291.51. 5,039,501 shares of the company’s stock traded hands, compared to its average volume of 5,631,433. AbbVie has a 52 week low of $190.75 and a 52 week high of $302.93. The stock has a fifty day moving average price of $271.98 and a two-hundred day moving average price of $239.04. The stock has a market capitalization of $515.27 billion, a price-to-earnings ratio of 50.17, a price-to-earnings-growth ratio of 1.32 and a beta of 0.20.